Key Developments: Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,756.30INR
12 Feb 2016
Change (% chg)

Rs-34.85 (-1.95%)
Prev Close
Rs1,791.15
Open
Rs1,810.00
Day's High
Rs1,810.00
Day's Low
Rs1,725.15
Volume
970,447
Avg. Vol
954,178
52-wk High
Rs2,129.00
52-wk Low
Rs1,586.10

Search Stocks

Latest Key Developments (Source: Significant Developments)

Lupin Ltd receives FDA approval for generic Generess tablets
Friday, 8 Jan 2016 03:52am EST 

Lupin Ltd:Says that it has received final approval for its KaitlibTM Fe Tablets (Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets, 75 mg) from United States Food and Drug Administration (FDA).To market generic version of Warner ChiIcott's Generess Fe Chewable Tablets, (Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets, 75 mg).  Full Article

Lupin Ltd receives FDA approvals for Generic Loestrin Fe 1/20 and Loestrin 1.5/30 Tablets
Tuesday, 24 Nov 2015 04:41am EST 

Lupin Ltd:Says that it has received FDA approvals for Generic Loestrin Fe 1/20 and Loestrin 1.5/30 Tablets.  Full Article

Lupin Ltd receives FDA approval for generic Loestrin 24 Fe Tablet
Tuesday, 3 Nov 2015 12:26am EST 

Lupin Ltd:Says that it has received final approval for its Blisovi 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) from US FDA to market a generic version of Warner Chilcott's Loestrin 24 Fe Tablets.  Full Article

Lupin Ltd Launches Generic PhosLo in the US
Monday, 26 Oct 2015 05:13am EDT 

Lupin Ltd:Has launched calcium acetate capsules, 667 mg having received final approval from the USFDA.  Full Article

Lupin Ltd launches first ever Duloxetine 40 mg Delayed-Release Capsules in the US
Thursday, 3 Sep 2015 06:53am EDT 

Lupin Ltd:Announces that its subsidiary has launched its Duloxetine 40 mg Delayed-Release Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength.  Full Article

Lupin Ltd receives FDA approval for Generic Prilosec Capsules
Thursday, 27 Aug 2015 06:15am EDT 

Lupin Ltd:Has received final approval for its Omeprazole Delayed-Release capsules 40 mg from the USFDA to market a generic version of AstraZeneca Pharmaceuticals LP Prilosec Delayed-Release capsules 40 mg.  Full Article

Lupin Ltd receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg
Thursday, 20 Aug 2015 07:42am EDT 

Lupin Ltd:Receives FDA approval for Fenofibrate Tablets, 54 mg and 160 mg.  Full Article

Lupin Ltd announces New Center of Excellence for Inhalation Research in Florida
Friday, 7 Aug 2015 07:43am EDT 

Lupin Ltd:Announces opening of its new center of excellence for Inhalation Research in Coral Springs, Florida.  Full Article

Lupin Ltd announces acquires specialty product portfolio in Germany
Friday, 24 Jul 2015 08:11am EDT 

Lupin Ltd:Has entered into a strategic asset purchase agreement with Temmler Pharma Gmbh & Co. KG a part of the Aenova Group, to acquire Temmler's specialty product portfolio subject to certain closing conditions.  Full Article

Lupin Ltd acquires GAVIS to Expand US Generic Business
Thursday, 23 Jul 2015 05:30am EDT 

Lupin Ltd:Says has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS), subject to certain closing conditions, in a transaction valued at $ 880 mln, cash free and debt free.  Full Article

Photo

Lupin expects diabetes drug sales to lift Q4 profit

MUMBAI Lupin Ltd, India's third-largest drugmaker, reported a quarterly profit that met estimates as strong sales in its local market help offset weakness in the United States, and the company said it expects fourth-quarter earnings to improve.

Search Stocks